LYL314

PreclinicalSmall molecule

LLyell Immunopharma, Inc.

LYL314 is one of 4 small molecule programs targeting Relapsed Non-Hodgkin Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed Non-Hodgkin LymphomaRecruiting

Relapsed Non-Hodgkin LymphomaPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Relapsed Non-Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

1 2

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 3

Rondecabtagene Autoleucel

LLyell Immunopharma, Inc.

Preclinical

1 4

LYL314

LLyell Immunopharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

PreclinicalRecruiting

Relapsed Non-Hodgkin Lymphoma

NCT05826535

Clinical

Trials by Indication[1]

Relapsed Non-Hodgkin Lymphoma1 trial

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

Recruiting·LLyell Immunopharma, Inc.·Preclinical·NCT05826535·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LYL314. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LYL314 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LYL314. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lyell Immunopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLyell Immunopharma, Inc.

LYL314

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Relapsed Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News